Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Shilpa Gupta, Yohann Loriot, Michiel S. van der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Aude Fléchon, Daniel P. Petrylak, Maria De Santis, Matthew D. Galsky, Jae‐Lyun Lee, Umang Swami, Srikala S. Sridhar, Ugo De Giorgi, Phoebe Wright, Vanessa Shih, Yi‐Tsung Lu, Xuesong Guan, Ryan Dillon, Aditya Shetty, Blanca Homet Moreno, Jennifer L. Beaumont, Intan Purnajo, Shauna McManus, Thomas Powles